ProfileGDS5678 / 1418565_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 69% 65% 64% 66% 65% 64% 67% 65% 64% 65% 65% 65% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9509165
GSM967853U87-EV human glioblastoma xenograft - Control 24.2750469
GSM967854U87-EV human glioblastoma xenograft - Control 33.9336265
GSM967855U87-EV human glioblastoma xenograft - Control 43.7971164
GSM967856U87-EV human glioblastoma xenograft - Control 53.9279566
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9684265
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8741564
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1075367
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9047265
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8246164
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9042565
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8900365
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9119765
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.923165